Zelda’s cannabis trial for autism goes ahead

Company News

by Rachael Jones

Perth-based clinical trials company Zelda Therapeutics (ASX:ZLD) now has approval for their autism project involving cannabis to be conducted at the USA-based Children’s Hospital of Philadelphia.

The Institutional Review Board Approval is the equivalent to Human Research Ethics Approval here in Australia.

It essentially allows the planned study to commence within the parameters of the approved trial protocols.

The study will monitor paediatric patients already being treated with medicinal cannabis formulations.

It will identify the appropriate dosage and effectiveness.

Shares in Zelda Therapeutics (ASX:ZLD) closed flat at $0.10
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.